Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ono Pharmaceutical Co., Ltd.
With
Bristol-Myers Squibb
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with histologically- or cytologically-confirmed non-squamous non-small cell lung cancer
Subjects who received a diagnosis of stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation according to the UICC-TNM Classification (7th edition) with no prior systemic anticancer therapy
Subjects with at least one measurable lesion by radiographic tumor assessments per RECIST 1.1 criteria
Subjects who are able to provide tumor tissue specimens.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
You may not be if
Subjects with known EGFR mutations, including deletions in exon 19 and exon 21 (L858R) substitution mutations.
Subjects with known ALK translocations.
Complication or history of severe hypersensitivity reactions to antibody products or platinum-containing compounds
Subjects with autoimmune disease or known chronic or recurrent autoimmune disease.
Subjects with multiple cancer.
Clareo Health | Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)
